KDOQI Commentary on the KDIGO 2022 Update to the Clinical Practice Guideline for Diabetes Management in CKD

By sjmartinez • December 25, 2023

Mottl AK, Nicholas SB. KDOQI Commentary on the KDIGO 2022 Update to the Clinical Practice Guideline for Diabetes Management in CKD. Am J Kidney Dis. 2023 Dec 21:S0272-6386(23)00883-1. doi: 10.1053/j.ajkd.2023.09.003. Epub ahead of print. PMID: 38142396.

Tags: Chronic kidney disease, commentary, diabetes, evidence-based recommendation, GLP-1 RAs, guideline, guideline implementation, Nephrology, nephrology best practices, ns-MRAs, Publications, SGLT2 inhibitors

The sigma1 receptor is a target for the development of cardioprotective drugs

Maslov LN, Tsirulnikov K, Slidnevskaya AS, Kilin M, Kan A, Grab AE, Gorbunov AS, Singh N. The σ1receptor is a target for the development of[...]

Calcific Changes in an End-Stage Kidney following Long-Term Dialysis, Tertiary Hyperparathyroidism, and Treatment for Complement-Mediated Thrombotic Microangiopathy: A Case Report

Shah KG, Adler SG, Dai T, Nast CC. Calcific Changes in an End-Stage Kidney following Long-Term Dialysis, Tertiary Hyperparathyroidism, and Treatment for Complement-Mediated Thrombotic Microangiopathy:[...]

The Role of Online Hemodiafiltration in Contemporary Kidney Care

Ronco C, Maduell F, Kalantar-Zadeh K, Madero M, Reis T. The Role of Online Hemodiafiltration in Contemporary Kidney Care. Clin J Am Soc Nephrol. 2025[...]